澳洲幸运5开奖号码历史查询

Johnson & Johnson Stock Rises on Better-Than-Expected Revenue, Adjusted Profit

Johnson & Johnson logo at company office in California.

Mario Tama / Getty Images

Key Takeaways

  • Johnson & Johnson shares advanced Tuesday after the pharmaceutical and medical device company posted better third-quarter sales and adjusted profit than expected.
  • Net income fell sharply due to billions in one-time expenses like legal costs.
  • Johnson & Johnson also lifted its full-year sales outlook, but lowered profit projections to account for a recently completed acquisition.

Johnson & Johnson (JNJ) shares advanced Tuesday after the p꧒harmaceutical and m♔edical device company posted better third-quarter sales and adjusted profit than expected.

Johnson & Johnson reported $22.47 billion in revenue, up 5% year-over-year and better than 澳洲幸运5开奖号码历史查询:analysts had projected, according to estimates compiled by Visible Alpha. It registered $2.69 billion in 澳洲幸运5开奖号码历史查询:net income, down 38% and well short of expectation, on billions in one-time expenses like legal costs and 澳洲幸运5开奖号码历史查询:acquisitions.

Adjusted Profit Beats Estimates

After accounting for over $3 billion in one-time 澳洲幸运5开奖号码历史查询:expenses like legal costs, "intangible 澳洲幸运5开奖号码历史查询:asset amortization expense," and the cost of acq♛uisitions, Johnson & Johnson's adjusted profit of $5.88 billion came in more than half a billion dollars higher than expected.

The company also adjusted its 澳洲幸运5开奖号码历史查询:full-year outlook, lifting sales projections to $88.4 billion to $88.8 billion from the prior range of $88 billion to $88.4 billion. Still, Johnson & Johnson lowered its adjusted 澳洲幸运5开奖号码历史查询:earnings per share (EPS) projections to $9.88 per share to $9.98 per share from $9.97 to $10.07 to account for the impact of its recently completed acquisition of V-Wave, which develops 澳洲幸运5开奖号码历史查询:treatments for heart failure.

澳洲幸运5开奖号码历史查询:Chief Executive Officer (CEO) Joaquin Duato said the company's recent drug approvals and development miಞlestones of other proje💎cts is "further strengthening our confidence in our near- and long-term growth targets."

Johnson & Johnson shares fell in premarket trading after th🍸e report butꦦ were up 2% in late-morning trading. They are about 5% higher this year.

UPDATE—Thi꧑s story has been updated with the latest share price information.

Do you have a news tip for Investopedia reporters? Please email us at
Article Sources
Investopedia requires writers to use primary sources to support their work. These include white papers, government data, original reporting, and interviews with industry experts. We also reference original research from other reputable publishers where appropriate. You can learn more about the standards we follow in producing accurate, unbiased content in our editorial policy.
  1. Johnson & Johnson. "."

Compare Accounts
The offers that appear in this table are from partnerships from which Investopedia receives compensation. This compensation may impact how and where listings appear. Investopedia does not include all offers available in the marketplace.

Related Articles